{"id":"ivermectin-and-doxycycline","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Photosensitivity (doxycycline)"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ivermectin is an antiparasitic agent that binds to glutamate-gated and GABA-gated chloride channels in nematodes and arthropods, causing paralysis and death. Doxycycline is a broad-spectrum tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. This combination is being investigated for synergistic activity against parasitic and bacterial infections, potentially including intracellular pathogens.","oneSentence":"Ivermectin paralyzes parasites by enhancing GABA-gated chloride channel activity, while doxycycline inhibits bacterial protein synthesis; together they target parasitic and bacterial co-infections.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:48:59.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parasitic and bacterial co-infections (investigational combination therapy)"}]},"trialDetails":[{"nctId":"NCT04482686","phase":"PHASE1","title":"Trial of Combination Therapy to Treat COVID-19 Infection","status":"COMPLETED","sponsor":"ProgenaBiome","startDate":"2020-12-09","conditions":"COVID, Covid-19, Corona Virus Infection","enrollment":31},{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT02366884","phase":"PHASE2","title":"Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)","status":"UNKNOWN","sponsor":"Dr. Frank Arguello Cancer Clinic","startDate":"2011-07-26","conditions":"Neoplasms","enrollment":250},{"nctId":"NCT04729140","phase":"PHASE4","title":"An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization","status":"UNKNOWN","sponsor":"Max Health, Subsero Health","startDate":"2020-12-28","conditions":"Covid19","enrollment":150},{"nctId":"NCT03075891","phase":"PHASE4","title":"Oracea Soolantra Association in Participants With Severe Rosacea","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2017-07-05","conditions":"Rosacea","enrollment":273},{"nctId":"NCT04407130","phase":"PHASE2","title":"Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2020-06-16","conditions":"COVID-19 Patients","enrollment":72},{"nctId":"NCT04591600","phase":"PHASE1, PHASE2","title":"Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients","status":"COMPLETED","sponsor":"Alkarkh Health Directorate-Baghdad","startDate":"2020-07-01","conditions":"Covid19","enrollment":140},{"nctId":"NCT04523831","phase":"PHASE3","title":"Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection","status":"COMPLETED","sponsor":"Dhaka Medical College","startDate":"2020-06-01","conditions":"Covid19","enrollment":400},{"nctId":"NCT04551755","phase":"PHASE2","title":"Safety and Efficacy of Ivermectin and Doxycycline in Treatment of Covid-19","status":"UNKNOWN","sponsor":"Bangladesh Medical Research Council (BMRC)","startDate":"2020-09","conditions":"Covid19","enrollment":188},{"nctId":"NCT04434144","phase":"","title":"A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh","status":"COMPLETED","sponsor":"Upazila Health & Family Planning Officer's (UHFPO) Office, Chakoria, Cox's Bazar","startDate":"2020-05-02","conditions":"Ivermectin, Hydroxychloroquine, COVID19","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Imac and Doxibac"],"phase":"phase_3","status":"active","brandName":"Ivermectin and Doxycycline","genericName":"Ivermectin and Doxycycline","companyName":"Bangladesh Medical Research Council (BMRC)","companyId":"bangladesh-medical-research-council-bmrc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ivermectin paralyzes parasites by enhancing GABA-gated chloride channel activity, while doxycycline inhibits bacterial protein synthesis; together they target parasitic and bacterial co-infections. Used for Parasitic and bacterial co-infections (investigational combination therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}